Analysts expect Can-Fite BioPharma Ltd. to report revenue of 413,477.84 for 2026, against a range of 376,405.00 to 450,550.68. The most recent reported year, 2025, came in at 405,000.00, a 115.0% beat against the 188,341.77 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 853,000.00 | 810,000.00 | 743,000.00 | 674,000.00 | 405,000.00 | - | - | ||
| High Estimate | 871,273.78 | 1.24 M | 695,514.73 | 0.00 | 206,102.78 | 450,550.68 | 409,702.21 | ||
| Low Estimate | 721,210.78 | 1.14 M | 644,661.73 | 0.00 | 170,580.76 | 376,405.00 | 382,117.59 | ||
| Consensus Estimate | 796,242.28 | 1.19 M | 670,088.23 | 0.00 | 188,341.77 | 413,477.84 | 395,909.90 |
Analysts expect Can-Fite BioPharma Ltd. to report earnings per share of -1.90 for 2026, against a range of -2.07 to -1.73. The most recent reported year, 2025, came in at -5.97 , in line with the -0.49 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -6.00 | -60.00 | -60.00 | -10.59 | -5.97 | - | - | ||
| High Estimate | -95.76 | -63.51 | -25.65 | -23.71 | -0.45 | -1.73 | -0.83 | ||
| Low Estimate | -112.64 | -72.09 | -31.25 | -27.31 | -0.53 | -2.07 | -0.95 | ||
| Consensus Estimate | -104.20 | -67.80 | -28.45 | -25.51 | -0.49 | -1.90 | -0.89 |
Pull Wall Street consensus for Can-Fite BioPharma Ltd. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=CANF&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "CANF", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=CANF&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();